Pyxis Oncology (NASDAQ:PYXS) Releases Earnings Results, Beats Estimates By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) announced its quarterly earnings data on Monday. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.06, FiscalAI reports. The business had revenue of $11.04 million for the quarter.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.47 on Monday. The firm has a market cap of $91.52 million, a price-to-earnings ratio of -0.92 and a beta of 1.45. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.55. The firm has a 50 day moving average price of $1.54 and a two-hundred day moving average price of $2.52.

Institutional Investors Weigh In On Pyxis Oncology

Several large investors have recently modified their holdings of PYXS. Maia Wealth LLC bought a new position in Pyxis Oncology during the fourth quarter worth $25,000. Engineers Gate Manager LP bought a new stake in Pyxis Oncology during the fourth quarter valued at $26,000. Fox Run Management L.L.C. bought a new stake in Pyxis Oncology during the fourth quarter valued at $26,000. XTX Topco Ltd acquired a new stake in Pyxis Oncology during the 2nd quarter worth about $40,000. Finally, LPL Financial LLC raised its position in shares of Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after acquiring an additional 21,100 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PYXS. HC Wainwright lifted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Stephens raised their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Royal Bank Of Canada decreased their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pyxis Oncology currently has an average rating of “Moderate Buy” and an average target price of $7.20.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.